WORLD NEWS

This new agreement builds on a multi-year partnership between BioNTech and the UK government that began in January 2023.

The diabetes division, which generated nearly US$2.8 billion in sales in the fiscal year ending April 2025—a 10.7% increase from the previous year—is currently home to about 8,000 employees worldwide and is headquartered in Northridge, California.

The goal of this project is to support the development of advanced medical training simulators not only in Moscow but throughout Russia.

The company plans to resubmit the application later this year, once it has additional vaccine efficacy data from a late-stage clinical trial of its experimental seasonal influenza vaccine, mRNA-1010, which is expected to report results this summer.

This acquisition is set to expand Sanofi’s pipeline with a promising investigational treatment for Alzheimer’s disease, VG-3927.

This partnership aims to develop innovative siRNA-based treatments targeting neuroscience, immunology, and oncology—areas AbbVie considers strategic priorities.

This study aims to evaluate whether a new ultra-low X-ray dose technology can significantly reduce radiation exposure during coronary artery procedures without compromising image quality or procedural performance.

The partnership with Rznomics strengthens Lilly’s multi-pronged approach to hearing restoration, combining both gene therapy and RNA-editing platforms.

The new agreement represents a major step forward in global health cooperation, designed to make the world safer and more equitable when responding to future pandemics.

Lars Fruergaard Jørgensen, who has served as CEO since January 2017, will step down from his role by mutual agreement with the Board.